About

Eiko Lifesciences Ltd operates in Specialty Chemicals within the Materials sector.

Face value: ₹10

Market cap

₹70 Cr

P/E

40.0×

P/B

1.0×

Dividend yield

0%

ROE

5.8%

ROCE

7.7%

Debt / equity

0.02

OPM

7.9%

EPS (TTM)

₹1.2

Book value

₹47.0

52-week high

₹62.0

52-week low

₹43.9

₹48.7-8.3%1Y

Beta

0.36

Damps index moves

Volatility (1y)

37.9%

Annualised, daily returns

RSI (14)

58.7

Neither overbought nor oversold

Rel. strength (1y)

-17%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Profit CAGR of 42.5% over the last 5 years
+Revenue CAGR of 28.6% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 30.5×

Cons

−Low return on equity of 3.6% (3-yr avg)
−Thin operating margin of 7.9%

Research score

Structured signal from quality, growth, valuation and momentum.

46/100

Business quality: 44
Growth: 75
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Gujarat Fluorochemicals LimitedFLUOROCHEMFLUOROCHEM	₹47,713 Cr	₹49,912 Cr	₹5,303 Cr	₹1,375 Cr	25.8%	₹615 Cr	11.5%	11.1%	7.6%	401
Navin Fluorine International LimitedNAVINFLUORNAVINFLUOR	₹41,740 Cr	₹42,967 Cr	₹3,634 Cr	₹1,232 Cr	32.6%	₹790 Cr	20%	21.6%	20.1%	61
Aether Industries LimitedAETHERAETHER	₹22,161 Cr	₹22,603 Cr	₹1,224 Cr	₹384 Cr	31.3%	₹235 Cr	19.8%	13.2%	9.4%	330
Atul LimitedATULATUL	₹17,231 Cr	₹17,411 Cr	₹6,643 Cr	₹1,189 Cr	16.4%	₹704 Cr	11%	14.1%	11.5%	70
Aarti Industries LimitedAARTIINDAARTIIND	₹16,869 Cr	₹21,790 Cr	₹9,012 Cr	₹1,337 Cr	14.1%	₹531 Cr	5.1%	8.8%	7.3%	54
Fine Organic Industries LimitedFINEORGFINEORG	₹15,752 Cr	₹15,797 Cr	₹2,472 Cr	₹535 Cr	20.4%	₹438 Cr	17.6%	21.6%	16.8%	113
Basf India LimitedBASFBASF	₹14,796 Cr	₹14,796 Cr	₹16,177 Cr	₹952 Cr	4.4%	₹643 Cr	2.8%	14%	11.1%	40
Privi Speciality Chemicals LimitedPRIVISCLPRIVISCL	₹13,970 Cr	₹14,980 Cr	₹2,671 Cr	₹666 Cr	25.2%	₹342 Cr	12.4%	27.7%	25.2%	158
Sudeep Pharma LimitedSUDEEPPHRMSUDEEPPHRM	₹13,546 Cr	₹13,694 Cr	₹676 Cr	₹233 Cr	34.6%	₹133 Cr	27.1%	31.1%	25.2%	366
Anupam Rasayan India LimitedANURASANURAS	₹13,243 Cr	₹15,058 Cr	₹2,535 Cr	₹563 Cr	22.2%	₹175 Cr	9.4%	9.1%	5.5%	377
Vinati Organics LimitedVINATIORGAVINATIORGA	₹12,528 Cr	₹12,528 Cr	₹2,381 Cr	₹665 Cr	29.4%	₹448 Cr	19.9%	18.8%	14.9%	152
Elantas Beck India LimitedELANTASELANTAS	₹10,644 Cr	₹10,644 Cr	₹778 Cr	₹147 Cr	20.3%	₹136 Cr	17.4%	20.6%	15.8%	70

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	0	0	12	25	18	28	32	42
COGS	—	—	—	11	23	16	25	29	37
Gross profit	—	—	—	1	3	2	3	3	5
	0	0	0	1	2	1	1	2	2
	0	0	0	1	1	1	2	2	3
OPM %	60.9%	43.2%	52.8%	4.3%	5.2%	5.2%	5.8%	5.3%	7.9%
Depreciation	0	0	0	0	1	1	1	1	1
Interest	0	0	0	0	0	0	0	0	0
	—	—	—	0	1	1	0	1	2
Profit before tax	0	0	0	1	1	1	1	2	5
Tax	0	—	0	0	0	0	0	1	1
Tax %	22.7%	—	7.7%	26.5%	25.5%	25.2%	23.5%	25%	24%
	0	—	0	1	1	1	1	2	4
PAT margin %	39.1%	—	36.1%	5.1%	2.8%	4.2%	2.7%	5.4%	8.5%
EPS (₹)	1.3	—	0.3	1.6	0.9	0.9	0.7	1.3	2.6
EPS adjusted (₹)	—	—	—	1.6	0.9	0.9	0.6	1.3	2.5
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	4	8	8	13	14	14
Reserves	9	20	21	38	43	53
	2	5	0	0	2	2
	2	2	2	2	2	14
Total equity & liabilities	17	35	31	53	60	83
	0	14	14	14	14	14
CWIP	—	—	—	—	0	0
Investments	0	0	0	4	7	15
	16	20	17	35	39	54
Total assets	17	35	31	53	60	83

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-1	-8	4	-7	2	7
	-3	1	1	-1	-10	-11
	8	3	-5	20	6	6
Net cash flow	4	-4	0	13	-2	2
Free cash flow	-1	-8	4	-7	1	7
CFO / Operating profit %	-159.6%	-590.1%	444.2%	-439.8%	119.9%	207.2%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	11.4%	11.2%	12.2%	9%	10.1%	11.5%
EBITDA margin %	43.2%	52.8%	4.3%	5.2%	5.2%	5.8%	5.3%	7.9%
EBIT margin %	27%	36.1%	3.8%	2.9%	1.7%	3.4%	3.3%	6.5%
PAT margin %	—	36.1%	5.1%	2.8%	4.2%	2.7%	5.4%	8.5%
Working capital
Receivable days	—	—	104	65	142	172	114	164
Inventory days	—	—	2	88	21	49	50	39
Payable days	—	—	65	22	24	20	14	122
NWC days	—	—	41	132	138	200	150	81
Leverage
Current ratio	—	—	2.7	2.07	7.75	20.62	12.52	2.65
Debt to EBITDA	—	—	3.38	3.47	0	0	1.03	0.5
Debt to equity	—	—	0.14	0.16	0	0	0.03	0.02
Interest coverage	3.3	1.9	10.2	3.1	7.9	8.1	16.2	30.5
Asset turnover	—	—	0.72	0.73	0.59	0.53	0.54	0.51
Return ratios
Return on assets %	—	—	3.7%	2%	2.5%	1.4%	2.9%	4.3%
Return on capital employed %	—	—	7.3%	6.8%	4%	2.8%	3.8%	7.7%
Return on equity %	—	—	4.9%	2.5%	2.6%	1.5%	3.1%	5.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	24.23%	24.23%	24.23%	24.4%	24.4%	31.27%	36.23%	36.74%	37.17%	37.17%	39.91%	39.91%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	75.77%	75.77%	75.77%	75.6%	75.6%	68.73%	63.77%	63.26%	62.83%	62.83%	60.09%	60.09%
No. of shareholders	—	—	—	—	—	—	—	—	3,150	3,092	2,969	3,019

Promoter holding up 15.68 percentage points since Sep 2023.

53 deals · 24 Mar 2022 – 25 Jun 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
25 Jun 2025	SIDDHANT LAXMIKANT KABRA	Bulk	BSE	Buy	71,000	₹49.06	₹0.35 Cr
27 Mar 2025	2B BLACK BIO LLP	Bulk	BSE	Sell	1,37,000	₹51.67	₹0.71 Cr
27 Mar 2025	SIDDHANT LAXMIKANT KABRA	Bulk	BSE	Buy	1,30,000	₹51.65	₹0.67 Cr
18 Feb 2025	SIDDHANT LAXMIKANT KABRA	Bulk	BSE	Buy	73,000	₹50.73	₹0.37 Cr
18 Feb 2025	2B BLACK BIO LLP	Bulk	BSE	Sell	68,199	₹50.70	₹0.35 Cr
11 Jul 2024	ARITRO ASHISH ROY	Bulk	BSE	Sell	1,52,550	₹66.85	₹1.02 Cr
11 Jul 2024	JOYANTAKUMARJANA	Bulk	BSE	Buy	83,350	₹67.49	₹0.56 Cr
10 Jul 2024	SAURABHTRIPATHI	Bulk	BSE	Buy	80,000	₹59.77	₹0.48 Cr
5 Jul 2024	ARITRO ASHISH ROY	Bulk	BSE	Sell	1,07,415	₹51.00	₹0.55 Cr
6 Jun 2024	ARITRO ASHISH ROY	Bulk	BSE	Sell	76,100	₹49.03	₹0.37 Cr

1–10 of 53

1 / 6

Mr. LAXMIKANT RAMPRASAD KABRANon-Executive - Non Independent Director-Chairperson
Mr. BHAVESH DHIRAJLAL TANNANon-Executive - Non Independent Director
Mr. RAJKUMAR GOVINDAS BAHETINon-Executive - Independent Director
Ms. KAJAL DHANPATRAJ KOTHARINon-Executive - Independent Director
Mr. SUMUKH PRABHAKAR VARTAKExecutive Director
Ms. HASTI ARJAV DOSHINon-Executive - Independent Director
Mr. Jaid Ismail KojarChief Financial Officer
Mr. Chintan B. DoshiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Eiko Lifesciences Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

14

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Dividend dividend20 Sept 2017 · ex-date₹0.25

1

Board meeting to consider results12 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

20 announcementsExport CSV

25 May 2026, 5:09 pmCompany Update

Compliances-Reg.24(A)-Annual Secretarial Compliance

Reg.24(A)-Annual Secretarial Compliance PDF

21 May 2026, 5:31 pmBoard Meeting

Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ending On 31St March, 2026, In Accordance With Regulation 33 Of The SEBI Listing Regulation.

Exchange filing PDF

9 Apr 2026, 6:27 pmCompany Update

Non Applicability Of Annual Disclosure As Per SEBI Circular - Fund Raising By Issuance Of Debt Securities By Large Corporates.

General PDF

8 Apr 2026, 1:14 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

Date	Category	Subject	Filing
25 May 2026, 5:09 pm	Company Update Reg.24(A)-Annual Secretarial Compliance	Compliances-Reg.24(A)-Annual Secretarial Compliance	PDF
21 May 2026, 5:31 pm	Board Meeting	Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ending On 31St March, 2026, In Accordance With Regulation 33 Of The SEBI Listing Regulation.

Loading announcements…

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

1

Announcements

Not in the F&O segment

1

1

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends1

Board meetings1

Announcements

Not in the F&O segment

Dividends1

Board meetings1

Ratio timeline

No fund holdings on record

Announcements

Annual reports

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1

1

1